|
The Endeavour Capital Management Team has extensive experience in growing technology companies and realizing considerable shareholder value. The managers have a hands-on style when working with their portfolio companies to maximize opportunities using their combined experience and global networks.
Neville Jordan is a graduate engineer and holds an honorary Doctorate in Engineering, both from Canterbury University. His early work experience was in civil aviation and IBM. A rotary scholarship to the USA was then followed by several years in Europe as Vice President for a multinational company. In 1975 he founded MAS Technology Ltd, a telecommunications microwave company. He grew this from start-up to a significant multinational company and achieved a successful IPO on the NASDAQ main board. Neville then founded Endeavour Capital which invests in companies based on science and technology. He was awarded the United Kingdom IEE Kirby Medal for "outstanding eminence and distinction in advanced technology" and is a Distinguished Fellow of the Institute of Professional Engineers NZ. Neville has served on many government Ministerial Advisory committees, plus six years on the board of a Crown company, AgResearch, and three years each on the boards of the Foundation for Research Science & Technology and the Prime Minister's Growth and Innovation Advisory Board. He is a retired Officer of the RNZNVR and honorary Captain in the Royal NZ Navy. He has been Chair of several review Committees for both the Australian and NZ governments, most recently, the NZ government Taskforce reviewing Crown Research Institutes. In 1998 he established and chairs the Jordan Foundation which provides scholarships for higher learning, particularly for the disadvantaged, plus support for the performing arts. He has been made a Distinguished Life Member of the Downstage Theatre to recognise his contribution to live theatre. In 1999 he was invested into the New Zealand Order of Merit. He has received the Governor General's Supreme award for Exporting and is a laureate of both the Business Hall of Fame and the Hi-Tech Hall of Fame. He is the immediate Past President, Royal Society of NZ.
He served as a VP with Globalstar when it successfully listed on the NASDAQ exchange and his outward facing responsibilities included building the company’s global network of mobile communications Service Providers. A skilled relationship builder across business and national cultural borders, Bill has made a unique and strong contribution to many emerging companies. As a VP of Pionetics in the cleantech sector with A and B round VC investors, Bill served as Executive Director of their Beijing registered subsidiary. He has assisted several young companies with defensible IP across three continents seeking ‘A’ round funding to position themselves appropriately in engaging with major VC investors. These included:
Bill’s experience also includes having worked in a Blackstone
led team developing a restructuring plan for a public company. Separately
for a government backed R+D body he positioned a spin out for a
trade sale, and identified several potential buyers for the company.
His broad experience of the function and value of PE/VC investments
to companies at their appropriate stages of development provides
a unique perspective both to Endeavour as well as to our prospective
pipeline companies. Dennis was the founding partner and CEO of Rebis Inc., a San Francisco-based software company in the plant design CAE and CAD market. He grew the company from start-up in 1984 to become the worldwide leader in plant design applications for AutoCAD. In 1996, Rebis received an Inc. 500 award, as one of the top fastest growing private companies in the US, with 100 employees and annual revenues of US$13 million from 60 countries. Rebis was acquired by Bentley Systems in March 2002. In 1998 Dennis joined Cyra Technologies, Inc. to begin commercialization of a new 3D laser scanning system for AEC geomatic applications. By 2000, Cyra had a leadership position with over 65% market share in long range 3D laser scanning, with annual sales of US$10 million. In early 2001 Cyra was acquired by Leica Geosystems AG, for US$70 million. Dennis received a BE and ME from the University of Canterbury in civil engineering and a PhD from the University of California, Berkeley in 1978.
Stuart has been a General Partner at Endeavour since 2004. He is currently representing Endeavour on the boards of BioVittoria (natural, no calorie sweetener), FlexiDrill (rock drilling innovation), Simtrix (novel computer peripheral), Veritide (biological threat detection equipment for Homeland Defence), Glyvale (a medical device for diagnosing diabetes), ArcActive (nanotech company for a novel battery and a novel solar cell) and Photonic Innovations (laser based gas detection) and represents Endeavour for the investment in ProActa (anti-cancer drug development company). Stuart is a council member for the NZ Private Equity and Venture Capital Association, on the NZ board of the NZTE Beachheads Programme (selecting companies ready for international expansion), and is on the board of CRAG; the Commercialising Research Action Group, a partnership between industry and government on capturing value from R&D. He was also appointed to a Ministerial Advisory Group on Roading Costs in 2006. Prior to Endeavour, Stuart was a founder (with the late Howard Paterson) of Quest VC, an early stage investment company based in Dunedin. In this role he not only lead the investment process for a number of new ventures, he took an active role in managing investments in their formative stages. In the period from 1991 to 1999, Stuart worked in the civil engineering practice in a consulting engineering firm. He also lead the design of an infrastructure project that, in its day, was the largest council engineering project in NZ. He completed his career in engineering as the Regional Manager for a consulting practice, leading a team of 50 professionals. Stuart has a BE from Auckland University in Civil Engineering (1991),
a Diploma in Business from Auckland University, and an MBA from
Otago University (2000). Neil J. Campbell is currently the Founder and Chairman for Mosaigen™, Inc., a global healthcare & IT technology development corporation, headquartered in Rockville, Maryland USA. Mr. Campbell is also a member of the Adjunct Faculty of the Carey Graduate School of Business & Entrepreneurship at the Johns Hopkins University and lectures in the JHU Medical Schools. Mr. Campbell has held several industry executive positions over the past 23 years such as President & COO/CEO for EntreMed Biopharmaceuticals, a NASDAQ publicly-traded company; Senior Director of Commercial Development for Celera Genomics where he built U.S. and international sales, marketing & business development efforts; General Executive Management at Life Technologies, Inc., (acquired by Invitrogen) and IGEN, Inc. (acquired by Roche); and Abbott Laboratories, the diversified healthcare company. During his career, Mr. Campbell has successfully developed and/or
introduced over 200 products and services in the areas of high-performance
computing, medical software, e-commerce, pharmaceuticals, medical
devices, clinical diagnostics, consumer healthcare products, research
products, bioinformatics and nanotechnology. Mr. Campbell also has
extensive experience in raising capital from both the private and
public markets from seed/A round to public secondary offerings.
Mr. Campbell co-founded Quanta Biosciences of Gaithersburg, MD currently
serves as a director or advisor to several companies. |
For the latest information about Endeavour Capital's investment portfolio click here >>
People
Head
office contact details Endeavour Capital For further contact details, click here >>
|
Neville
Jordan CNZM 
Bill
Thatcher
Dennis
Row
Stuart
McKenzie
Neil
Campbell